Home › Research › Risk genes beyond APOE
Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD
Colton CA, Mott RT, Sharpe H, Xu Q, Van Nostrand WE, Vitek MP.. Journal of neuroinflammation, 2006-09-27
Topic: Brain proteins, microglia and lab models
Background Microglia are associated with neuritic plaques in Alzheimer disease (AD) and serve as a primary component of the innate immune response in the brain. Neuritic plaques are fibrous deposits composed of the amyloid beta-peptide fragments (Abeta) of the amyloid precursor protein (APP). Numerous studies have shown that the immune cells in the vicinity of amyloid deposits in AD express mRNA and proteins for pro-inflammatory cytokines, leading to the hypothesis that microglia demonstrate classical (Th-1) immune activation in AD.
Key findings
- Neuritic plaques are fibrous deposits composed of the amyloid beta-peptide fragments (Abeta) of the amyloid precursor protein (APP).
- Numerous studies have shown that the immune cells in the vicinity of amyloid deposits in AD express mRNA and proteins for pro-inflammatory cytokines, leading to the hypothesis that microglia demonstrate classical (Th-1) immune activation in AD.
- Nonetheless, the complex role of microglial activation has yet to be fully explored since recent studies show that peripheral macrophages enter an "alternative" activation state.
- Methods To study alternative activation of microglia, we used quantitative RT-PCR to identify genes associated with alternative activation in microglia, including arginase I (AGI), mannose receptor (MRC1), found in inflammatory zone 1 (FIZZ1), and chitinase 3-like 3 (YM1).
Why it matters
This study examined expression profiles for macrophage alternative activation genes in Alzheimer's disease and mouse models, finding that microglial activation is complex and not fully explored. It does not test or suggest any treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 46/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of neuroinflammation) |
| Journal's citation record | 2 / 4 | Journal of Neuroinflammation: journal h-index 216 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2006 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Laboratory or animal study (title names “mouse”) — scores zero |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 391 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 17.8 citations a year over 22 year(s) since 2006 |
| Impact for its field and year | 3 / 6 | Cited 7.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 16 other studies in this library |
| Still being cited | 1 / 4 | Cited 12 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Michael Peter Vitek: h-index 70 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Duke Medical Center: institution h-index 1,255 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 17005052) |
| Free to read | 2 / 2 | Free to read |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/1742-2094-3-27
- PubMed: 17005052
- Original source →
- Free full text: Journal of Neuroinflammation →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Colton, C. A., Mott, R. T., Sharpe, H., Xu, Q., Van Nostrand, W. E., & Vitek, M. P. (2006). Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. Journal of neuroinflammation. https://doi.org/10.1186/1742-2094-3-27
Vancouver
Colton CA, Mott RT, Sharpe H, Xu Q, Van Nostrand WE, Vitek MP. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. Journal of neuroinflammation. 2006. doi:10.1186/1742-2094-3-27. PMID: 17005052.
BibTeX
@article{colton2006-17005052,
author = {Colton, C. A. and Mott, R. T. and Sharpe, H. and Xu, Q. and Van Nostrand, W. E. and Vitek, M. P.},
title = {{Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD}},
journal = {Journal of neuroinflammation},
year = {2006},
doi = {10.1186/1742-2094-3-27},
pmid = {17005052},
url = {https://doi.org/10.1186/1742-2094-3-27}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
16 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.